<DOC>
	<DOCNO>NCT02033278</DOCNO>
	<brief_summary>Clinical trial phase II-III , double-blind , randomize , control placebo . There sufficient preliminary evidence consider intracoronary injection bone marrow progenitor cell viable , safe beneficial treatment patient dilate cardiomyopathy , although biological mechanism action bone marrow cell myocardium know . In project propose investigate comparatively biological clinical point view applicability regenerative therapy autologous bone marrow cell patient dilate cardiomyopathy .</brief_summary>
	<brief_title>Infusion Intracoronary Mononuclear Autologous Adult Expanded Stem Cells Bone Marrow Functional Recovery Patients With Idiopathic Dilated Cardiomyopathy Heart Failure .</brief_title>
	<detailed_description>The study population correspond male female patient idiopathic dilate cardiomyopathy . 51 patient diagnosed disease include . After inclusion , proceed random allocation study group control group 2:1 ratio , 34 patient treatment group 17 control group . The total duration expect 48 month : The inclusion period 24 month patient assign experimental group follow 24 month , whereas one ramdomized control group , folow-up 12 month . Upon completion , patient follow routine clinical practice . This double blind study , patient perform bone marrow harvest . All patient receive best medical treatment individualize ( ACEIs Angiotensin II receptor blocker , beta-blockers , diuretic eplerenone ) least 6 month prior participation clinical trial , situation stable pharmacological basal condition everyone . The bone marrow cell patient assign placebo group cryopreserved , trial complete , blind open patient randomize control group , may process route compassionate use mononuclear bone marrow cell previously frozen . The patient randomize experimental group treat conventional treatment + infusion autologous mononuclear bone marrow cell expand whereas patient randomize control group treat conventional treatment + infusion placebo . The main objective ass comparative efficacy intracoronary injection bone marrow stem cell autologous improve ventricular function patient idiopathic dilate cardiomyopathy receive conventional medical treatment , compare control group receive infusion placebo conventional medical treatment . The improvement ventricular function assess change angiographically determine ejection fraction . Secondary objective study : - To analyze predictor good clinical response , functional biological treatment adult stem cell autologous mononuclear bone marrow expand term functional recovery . The following parameter evaluate : Functional class ( NYHA ) , Natriuretic peptide B , Stress test ( exercise time ) , Echocardiographic parameter ventricular function , example LVEF ( % ) , TDV ( ml ) , TSV ( ml ) TAPSE ( m ) Biological parameter cellular functionality , example CD133 + , CD34 + , CD34 +/CD177 + CD34 +/CD38- % . - To determine , light obtain result , application protocol suitable cell therapy treatment dilate cardiomyopathy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>1 . Patients sexes age 18 70 year . 2 . Patients diagnose dilate cardiomyopathy establish echocardiography symptom / sign heart failure idiopathic etiology . 3 . Minimum evolution since diagnosis 6 month 4 . Absence coronary lesion test multislice CT / hemodynamic study realize incorporation patient clinical trial 6 previous month signature inform consent participation clinical trial . 5 . Patients stable medical therapy least 6 month prior enrollment ( individually adjust accord functional status ) . 6 . Ejection fraction leave ventricle &lt; 40 % ejection fraction leave ventricle 40 % 50 % leave ventricular telediastolic volume &gt; 110 ml/m2 . 7 . Presence sinus rhythm . 8 . Patients give informed consent participation clinical trial consent . 9 . Normal laboratory parameter , define : Leukocytes ≥ 3000 Neutrophils ≥ 1500 Platelets ≥ 100,000 Aspartate aminotransferase / Alanine aminotransferase ≤ 2.5 standard range institution Creatinine ≤ 2.5 mg / dl 10 . Women childbearing potential must negative result pregnancy test time inclusion study agree use medically approve method contraception study . 1 . Dilated cardiomyopathy toxic origin , ischemic storage disease . 2 . Recent history myocarditis . 3 . Patients amenable treatment resynchronization 4 . Patients active wait list heart transplantation . 5 . Coexistence serious systemic disease . 6 . Coexistence type blood disease 7 . Pregnant woman , lactate , childbearing age use effective contraception . 8 . Patients currently participate complete participation clinical trial period le 3 month . 9 . Patients malignant premalignant tumor 10 . Positive serology hepatitis B virus , hepatitis C virus human immunodeficiency virus . 11 . Patients time study entry take medication prohibit protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>